455
Participants
Start Date
August 3, 2016
Primary Completion Date
February 28, 2031
Study Completion Date
February 28, 2031
Ribociclib
Topotecan
Temozolomide
Everolimus
Adavosertib
Carboplatin
Olaparib
Irinotecan
Vistusertib
Nivolumab
Cyclophosphamide
Selumetinib
Enasidenib
Lirilumab
Fadraciclib
Cytarabine
Dexamethasone
Ceralasertib
Futibatinib
Capmatinib
Avelumab
Peposertib
RECRUITING
Rigshospitalet, Copenhagen
NOT_YET_RECRUITING
Ospedale Infantile Regina Margherita, Torino
RECRUITING
Hôpital de La Timone, Marseille
RECRUITING
Hospital del Nino Jesus, Madrid
RECRUITING
CHU Pellegrin, Bordeaux
RECRUITING
CHU Nantes, Nantes
RECRUITING
Hospital Universitario La Fe, Valencia
RECRUITING
CHU Angers, Angers
RECRUITING
Centre Oscar Lambret, Lille
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
Institut Curie, Paris
RECRUITING
Hôpital Armand Trousseau, Paris
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
RECRUITING
Pediatric and Adolescent Oncology The Royal Marsden Hospital, Sutton
ACTIVE_NOT_RECRUITING
Prinses Maxima Centrum, Utrecht
RECRUITING
Vall d'Hebron, Barcelona
RECRUITING
Birmingham Children's Hospital, Birmingham
RECRUITING
Great Ormond Street Hospital, London
RECRUITING
Royal Manchester Children's Hospital, Manchester
RECRUITING
Royal Victoria Infirmary, Newcastle
National Cancer Institute, France
OTHER_GOV
Gustave Roussy, Cancer Campus, Grand Paris
OTHER